Company news

Jazz Pharmaceuticals plc news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

August 9, 2021

Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results

August 2, 2021

National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia

July 21, 2021

Jazz Pharmaceuticals to Report 2021 Second Quarter Financial Results on August 3, 2021

July 19, 2021

Jazz Pharmaceuticals Announces Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Investor Webcast on July 20, 2021

July 12, 2021

Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

June 29, 2021

Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution

June 24, 2021

Jazz Pharmaceuticals Updates 2021 Financial Guidance to Include Recently Acquired GW Pharmaceuticals plc

June 16, 2021

Jazz Pharmaceuticals and Leading Cancer Organizations Collaborate to Launch First and Only Digital Hub Focused Exclusively on Emotional, Social and Physical Health Needs of Small Cell Lung Cancer Community

June 13, 2021

Jazz Pharmaceuticals Presents 18 Abstracts in Sleep Medicine at SLEEP 2021

June 8, 2021

Jazz Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference on June 2, 2021

May 25, 2021

Jazz to Present New Data at ASCO and EHA 2021 Meetings Showcasing Clinical Advances Across Hematology and Oncology Portfolio

May 19, 2021

Jazz Pharmaceuticals Completes Acquisition of GW Pharmaceuticals plc

May 4, 2021

Jazz Pharmaceuticals to Participate in Three Investor Conferences in May 2021

May 3, 2021

Jazz Pharmaceuticals Announces First Quarter 2021 Financial Results

May 3, 2021

Jazz Pharmaceuticals Announces Closing of Senior Secured Notes Offering

April 28, 2021

GW Pharmaceuticals Shareholders Approve Acquisition by Jazz Pharmaceuticals

April 22, 2021

Jazz Pharmaceuticals Prices $1.5 Billion Senior Secured Notes Offering

April 21, 2021

Jazz Pharmaceuticals Announces Proposed Private Offering of Senior Secured Notes

April 19, 2021

Jazz Pharmaceuticals to Report 2021 First Quarter Financial Results on May 4, 2021

April 18, 2021

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Idiopathic Hypersomnia

April 11, 2021

Jazz Pharmaceuticals Announces FDA Approval of Additional Indication for Vyxeos® (daunorubicin and cytarabine) for the Treatment of Secondary Acute Myeloid Leukemia in Pediatric Patients

March 29, 2021

Jazz Pharmaceuticals Announces Participation at the 10th Annual J.P. Morgan Napa Valley Forum

March 21, 2021

Jazz Pharmaceuticals and Hypersomnia Foundation Launch Campaign to Increase Understanding and Awareness of Idiopathic Hypersomnia

March 17, 2021

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results

February 22, 2021

Jazz Pharmaceuticals Completes Submission of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia

February 15, 2021

Jazz Pharmaceuticals to Report 2020 Fourth Quarter Financial Results on February 23, 2021

February 8, 2021

Jazz Pharmaceuticals to Acquire GW Pharmaceuticals plc, Creating an Innovative, High-Growth, Global Biopharma Leader

February 2, 2021

Jazz Pharmaceuticals Announces Participation in the 39th Annual J.P. Morgan Healthcare Conference

January 3, 2021

Jazz Pharmaceuticals Announces Initiation of Biologics License Application Submission for JZP-458 for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

December 20, 2020

Jazz Pharmaceuticals and PharmaMar Announce Results of ATLANTIS Phase 3 Study Evaluating Zepzelca™ in Combination with Doxorubicin for Patients with Small Cell Lung Cancer Following One Prior Platinum-containing Line

December 2, 2020

Jazz Pharmaceuticals Appoints Jennifer Cook and Mark Smith, M.D. to its Board of Directors

November 16, 2020

Jazz Pharmaceuticals Announces Participation at Jefferies Virtual London Healthcare Conference

November 9, 2020

Jazz Pharmaceuticals Announces Third Quarter 2020 Financial Results

November 1, 2020

Jazz Pharmaceuticals Acquires SpringWorks Therapeutics' FAAH Inhibitor Program

October 25, 2020

Jazz Pharmaceuticals Announces SLEEP Publication of Phase 3 Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Study in Cataplexy or Excessive Daytime Sleepiness in Patients with Narcolepsy

October 19, 2020

Jazz Pharmaceuticals Announces Webcast for Xywav Investor Update

October 18, 2020

Jazz Pharmaceuticals Announces Positive Top-line Results from Phase 3 Study of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution in Adult Patients with Idiopathic Hypersomnia

October 7, 2020

Jazz Pharmaceuticals Launches Initiative to Help Educate People Living with Rare Form of Leukemia

September 16, 2020

Jazz Pharmaceuticals Announces New Sleep Health Collaboration

September 14, 2020

Jazz Pharmaceuticals Announces New Research Collaboration with Redx Pharma to Discover and Develop Two Targeted Cancer Therapies

September 8, 2020

Jazz Pharmaceuticals Announces Second Quarter 2020 Financial Results

August 3, 2020

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy

July 21, 2020

Jazz Pharmaceuticals to Report 2020 Second Quarter Financial Results on August 4, 2020

July 20, 2020

Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca™ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer

June 14, 2020

Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 2.000% Exchangeable Senior Notes due 2026

June 8, 2020

Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2026

June 7, 2020

Jazz Pharmaceuticals Announces Participation at Two Upcoming Virtual Investor Conferences

May 26, 2020

Jazz Pharmaceuticals Announces Appointment Of Kim Sablich As Executive Vice President, General Manager Of North America

May 10, 2020

Jazz Pharmaceuticals Announces Participation at Upcoming Virtual Investor Conferences

May 5, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 18 calls. Every call is listed under its year.

Decks

The 5 newest of 37 decks. Every deck is listed under its year.